Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992249 · ClinicalTrials.gov registry record
Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases
A clinical trial, sponsored by Avita Medical.
- Completed
- Registry status
- 100
- Enrollment target
NCT02992249: Completed study, sponsored by Avita Medical.
NCT02992249 is a clinical trial that has completed, run by Avita Medical. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02992249 has completed, sponsored by Avita Medical.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This is a prospective uncontrolled observational study to evaluate clinical outcomes following use of the ReCell Autologous Cell Harvesting Device (ReCell) as an adjunct for closure (re-epithelialization) as a treatment of life-threatening wounds requiring grafting for closure, and associated skin graft donor sites, in patients who lack adequate available skin to harvest for conventional grafting. Treatment with the ReCell device may be performed as part of a single operative procedure, or multiple staged procedures as deemed clinically necessary. Adverse events associated with the use of the ReCell device/cell suspension will be documented. Subjects will be followed for 1 year following ReCell treatment.
Primary Outcome
\> 95% epithelialization with a contiguous layer of viable epithelium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-06 |
What the finished NCT02992249 record still lists
NCT02992249 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02992249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02992249 about?
NCT02992249 is a clinical study titled "Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases". This is a prospective uncontrolled observational study to evaluate clinical outcomes following use of the ReCell Autologous Cell Harvesting Device (ReCell) as an adjunct for closure (re-epithelialization) as a treatment of life-threatening wounds requiring grafting for closure, and associated skin g...
What is the current status of trial NCT02992249?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2014-05. Estimated completion is 2020-06.
Who is sponsoring clinical trial NCT02992249?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia